Once-daily oral icotrokinra outperforms placebo in ulcerative colitis

A Cedars-Sinai-led phase 2 double-blind trial found that oral IL-23 receptor blocker icotrokinra achieved 12-week clinical response rates of 63%, 58%, and 55% at doses of 400, 200, and 100 mg in ulcerative colitis patients, versus 27% with placebo. The 400 mg group showed clinical remission of 30% versus 11% and endoscopic improvement of 37% versus 14%.